Crossref

1. Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis

- Lorenzo Villa-Zapata

- Briggs S Carhart

- John R Horn

- Philip D Hansten

- Vignesh Subbian

- Sheila Gephart

- Malinda Tan

- Andrew Romero

- Daniel C Malone

2. Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity

- Aneesh Dhore-patil

- Tariq Thannoun

- Rohan Samson

- Thierry H. Le Jemtel

3. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy

- Li‐Jing Sun

- Yan‐Ni Sun

- Jian‐Ping Shan

- Geng‐Ru Jiang

4. Efficacy and safety of dual vs single renin–angiotensin–aldosterone system blockade in chronic kidney disease

- Mingming Zhao

- Hua Qu

- Rumeng Wang

- Yi Yu

- Meiying Chang

- Sijia Ma

- Hanwen Zhang

- Yuejun Wang

- Yu Zhang

5. Reporting Quality Assessment of Randomized Controlled Trials Published in Nephrology Urology Monthly Journal

- Alireza Mehrazmay

- Alireza Karambakhsh

- Mahmood Salesi

6. Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis

- Yanhuan Feng

- Rongshuang Huang

- Janet Kavanagh

- Lingzhi Li

- Xiaoxi Zeng

- Yi Li

- Ping Fu

7. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy

- Luxitaa Goenka

- Raghavan Padmanaban

- Melvin George

8. Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease

- 璇 王

9. Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy

- Songyan Wang

- Bing Li

- Chunguang Li

- Wenpeng Cui

- Lining Miao

10. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

- Nina Vodošek Hojs

- Sebastjan Bevc

- Robert Ekart

- Nejc Piko

- Tadej Petreski

- Radovan Hojs

11.

12. Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease

- Xian Chen

- Wenni Dai

- Hao Li

- Zhe Yan

- Zhiwen Liu

- Liyu He

13. Development, optimization, and assessment of losartan nano-bilosomes to mitigate diabetes-induced microvascular complications in Sprague Dawley rats

- Mona Qushawy

- Ghareb M. Soliman

- Yasmin Mortagi

- Mohamed El-Sherbiny

- Nehal Elsherbiny

14. Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33

- Tina Ghaffari

- Nariman Moradi

- Elham Chamani

- Zahra Ebadi

- Reza Fadaei

- Shahin Alizadeh-Fanalou

- Sahar Yarahmadi

- Soudabeh Fallah

15. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

- Daiji Kawanami

- Yuichi Takashi

- Yoshimi Muta

- Naoki Oda

- Dai Nagata

- Hiroyuki Takahashi

- Makito Tanabe

16. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes

- Dan Dong

- Ting-ting Fan

- Ying-shi Ji

- Jin-yu Yu

- Shan Wu

- Li Zhang

17. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population

- Romance Nguetse Djoumessi

- Jean Jacques N. Noubiap

- Francois Folefack Kaze

- Mickael Essouma

- Alain Patrick Menanga

- Andre Pascal Kengne

- Jean Claude Mbanya

- Eugene Sobngwi

18. Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome

- Diana Rubel

- Yanqin Zhang

- Nenja Sowa

- Rainer Girgert

- Oliver Gross